Home Newsfeeds Mizuho Maintains Neutral on Rapid7, Lowers Price Target to $40

Mizuho Maintains Neutral on Rapid7, Lowers Price Target to $40

Mizuho analyst Gregg Moskowitz maintains Rapid7 (NASDAQ:RPD) with a Neutral and lowers the price target from $45 to $40.

byBenzinga Newsdesk

December 8, 2022

1 minute read

Mizuho analyst Gregg Moskowitz maintains Rapid7 (NASDAQ:RPD) with a Neutral and lowers the price target from $45 to $40.

This DeFi Token Tops Gains With 22% Surge As Bitcoin, Ethereum Crawl Back Up

By Mehab Qureshi

December 4, 11:01 PM

Celo (CRYPTO: CELO), the native token of the mobile-first DeFi platform rose over 22% in the past 24 hours, topping CoinMarketCap’s gainer of the day.

$CELO

Analyst Ratings

What 4 Analyst Ratings Have To Say About Harley-Davidson

By Benzinga Insights

July 14, 3:05 PM

Analysts have provided the following ratings for Harley-Davidson (NYSE:HOG) within the last quarter:

HOG

Why Lipocine Stock Is Moving Higher Today?

By Vandana Singh

July 27, 12:22 PM

Lipocine Inc (NASDAQ: LPCN) shares are trading higher after the company released topline results from a Phase 2 clinical study of LPCN 1148, an oral candidate under development for the

LPCN

argenx Announces European Commission Approval of Subcutaneous VYVGART (Efgartigimod Alfa) for Generalized Myasthenia Gravis

By Benzinga Newsdesk

November 16, 8:41 AM

argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the European Commission (EC) approved SC

ARGX

Mizuho Maintains Neutral on Rapid7, Lowers Price Target to $40

Related Posts

This DeFi Token Tops Gains With 22% Surge As Bitcoin, Ethereum Crawl Back Up

What 4 Analyst Ratings Have To Say About Harley-Davidson

Why Lipocine Stock Is Moving Higher Today?

argenx Announces European Commission Approval of Subcutaneous VYVGART (Efgartigimod Alfa) for Generalized Myasthenia Gravis